Ginger Johnson

Company: Lumanity

Job title: Senior Vice President, Strategy Consulting

Seminars:

Panel Discussion: What Have we Learned from the Last 12 Months of Alzheimer’s Drug Development? 8:15 am

What have been the main obstacles to integrating first class of anti-amyloids into the treatment paradigm? What is the impact of ARIA on penetration of these new anti-amyloid therapies into market? What is the plan to better manage the burden of ARIA going forward? Shifting focus to new emerging therapies: From anti-inflammatory and anti-tau treatments…Read more

day: Conference Day One AM